The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera
Abstract
Purpose: The clinical course of polycythemia vera is often complicated by thrombosis as well as by the possible transition to myeloid metaplasia with myelofibrosis or acute myeloid leukemia. The aim of this study was to assess the rate of these complications in subjects receiving currently recommended treatments. Patients and Methods: Overall, 1,638 patients from 12 countries were enrolled onto a large, prospective multicenter project aimed at describing the clinical history of polycythemia vera for the following outcomes: survival, the cumulative rate of cardiovascular death and thrombosis, the cumulative rate of leukemia, myelodysplasia, and myelofibrosis. The mean duration of the disease at entry and the duration of the follow-up were 4.9 and 2.7 years, respectively. Results: The overall mortality rate of 3.7 deaths per 100 persons per year resulted from a moderate risk of cardiovascular death and a high risk of death from noncardiovascular causes (mainly hematologic transformations). Age older than 65 years and a positive history of thrombosis were the most important predictors of cardiovascular events. Antiplatelet therapy, but not cytoreductive treatment, was significantly associated with a lower risk of cardiovascular events. We found a consistent association between age and risk of leukemia, and between duration of the disease with risk of myelofibrosis. Conclusion: The European Collaboration on Low-Dose Aspirin in Polycythemia Vera study documents that large international collaborative studies are feasible in this field, in which few epidemiologic data are available. The persistently high mortality rate from hematologic malignancies characterizes the unmet therapeutic need of polycythemic patients and suggests a priority for future studies in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, D. A. G., GRALNICK, H. R., & SULTAN, C. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-620 · Cited by 2,926
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., & Barbui, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035572 · Cited by 1,012
Self-citationPolycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years
Policitemia*, G. I. S. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-9-199511010-00003 · Cited by 502
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Berk, P. D., Goldberg, J. D., Donovan, P. B., Fruchtman, S. M., Berlin, N. I., & Wasserman, L. R. (1986) · PubMed · Cited by 493
Increased Incidence of Acute Leukemia in Polycythemia Vera Associated with Chlorambucil Therapy
Berk, P. D., Goldberg, J. D., Silverstein, M. N., Weinfeld, A., Donovan, P. B., Ellis, J. T., Landaw, S. A., Laszlo, J., Najean, Y., Pisciotta, A. V., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198102193040801 · Cited by 492
Polycythemia vera: myths, mechanisms, and management
Spivak, J. L. (2002) · Blood · doi:10.1182/blood-2001-12-0349 · Cited by 463
VASCULAR OCCLUSIVE EPISODES AND VENOUS HÆMATOCRIT IN PRIMARY PROLIFERATIVE POLYCYTHÆMLX
Pearson, T. C., & Wetherley-Mein, G. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92098-6 · Cited by 381
Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
Rozman, C., Feliu, E., Giralt, M., Rubio, D., & Cortés, M.-T. (1991) · Cancer · doi:10.1002/1097-0142(19910515)67:10<2658::aid-cncr2820671042>3.0.co;2-c · Cited by 248
Cobalamin and folate deficiency: acquired and hereditary disorders in children.
Rosenblatt, D. S., & Whitehead, V. M. (1999) · PubMed · Cited by 156
Passamonti, F., Malabarba, L., Orlandi, E. M., Baratè, C., Canevari, A., Brusamolino, E., Bonfichi, M., Arcaini, L., Caberlon, S., Pascutto, C., et al. (2003) · PubMed · Cited by 105
PHYSIOPATHOLOGY AND COURSE OF POLYCYTHEMIA VERA AS RELATED TO THERAPY
Dameshek, W. (1950) · JAMA · doi:10.1001/jama.1950.02910290018005 · Cited by 85
Polycythemia Vera and the Myeloproliferative Disorders
Wasserman, L. R., Berk, P. D., & Berlin, N. I. (1995) · Medical Entomology and Zoology · Cited by 83
A Polycythemia Vera Update: Diagnosis, Pathobiology, and Treatment
Pearson, T. C., Messinezy, M., Westwood, N., Green, A. R., Bench, A. J., Green, A. R., Huntly, B. J. P., Nacheva, E. P., Barbui, T., & Finazzi, G. (2000) · Hematology · doi:10.1182/asheducation-2000.1.51 · Cited by 73
Self-citationLow‐dose aspirin in polycythaemia vera: a pilot study
Policitemia, G. I. S. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.362682.x · Cited by 66
Myeloproliferative disorders: complications, survival and causes of death
Brodmann, S., Passweg, J. R., Gratwohl, A. A., Tichelli, A., & Skoda, R. C. (2000) · Annals of Hematology · doi:10.1007/s002779900136 · Cited by 56
Feasibility of Randomised Clinical Trials in Rare Diseases: The Case of Polycythemia Vera
Marchioli, R., Landolfi, R., Barbui, T., & Tognoni, G. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609074369 · Cited by 6
Self-citation
Cited by
The Myeloproliferative Disorders
Campbell, P. J., & Green, A. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra063728 · Cited by 915
Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H. C., Hehlmann, R., Hoffman, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8436 · Cited by 849
Self-citationCardiovascular Events and Intensity of Treatment in Polycythemia Vera
Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., De Stefano, V., Elli, E., Iurlo, A., Latagliata, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208500 · Cited by 846
Self-citationCampbell, P. J., Scott, L. M., Buck, G., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 653
Kiladjian, J.-J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C., & Fenaux, P. (2008) · Blood · doi:10.1182/blood-2008-03-143537 · Cited by 583
Metadata
- Authors
- Marchioli, R., Finazzi, G., Landolfi, R., Kutti, J., Gisslinger, H., Patrono, C., Marilus, R., Villegas, A., Tognoni, G., & Barbui, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-04-01
- Volume
- 23
- Issue
- 10
- Pages
- 2224-2232
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149373649
- Cited by
- 726
- References
- 17
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.